1. Academic Validation
  2. Combinatorial allosteric modulation of agonist response in a self-interacting G-protein coupled receptor

Combinatorial allosteric modulation of agonist response in a self-interacting G-protein coupled receptor

  • Commun Biol. 2020 Jan 15;3(1):27. doi: 10.1038/s42003-020-0752-4.
Marco Patrone 1 Eugenia Cammarota 2 Valeria Berno 3 Paola Tornaghi 1 Davide Mazza 2 Massimo Degano 4
Affiliations

Affiliations

  • 1 Biocrystallography Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • 2 Center for Experimental Imaging, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • 3 Advanced Light and Electron Microscopy Bioimaging Center ALEMBIC, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • 4 Biocrystallography Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. [email protected].
Abstract

The structural plasticity of G-protein coupled receptors (GPCRs) enables the long-range transmission of conformational changes induced by specific orthosteric site ligands and other pleiotropic factors. Here, we demonstrate that the ligand binding cavity in the sphingosine 1-phosphate receptor S1PR1, a class A GPCR, is in allosteric communication with both the β-arrestin-binding C-terminal tail, and a receptor surface involved in oligomerization. We show that S1PR1 oligomers are required for full response to different agonists and ligand-specific association with arrestins, dictating the downstream signalling kinetics. We reveal that the active form of the immunomodulatory drug fingolimod, FTY720-P, selectively harnesses both these intramolecular networks to efficiently recruit β-arrestins in a stable interaction with the receptor, promoting deep S1PR1 internalization and simultaneously abrogating ERK1/2 phosphorylation. Our results define a molecular basis for the efficacy of fingolimod for people with multiple sclerosis, and attest that GPCR signalling can be further fine-tuned by the oligomeric state.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18991
    98.69%, GRK Inhibitor
    PKA